Actym to Present Preclinical Data on Clinical Candidate ACTM-838 at 38th SITC Annual Meeting
BERKELEY, CA, November 3, 2023 Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today that it will present preclinical data of its lead asset, ACTM-838, in a poster presentation at the 2023 38th Society for Immunotherapy of Cancer (SITC) Annual Meeting in San Diego, California. The presentation will feature data examining […]
This article is featured on another website.
Windtree to Present at the Dawson James Small Cap Growth Conference on October 12th
WARRINGTON, Pa. , Oct. 03, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that Craig Fraser , President and Chief Executive
Windtree to Present at the Dawson James Small Cap Growth Conference on October 12th
WARRINGTON, Pa. , Oct. 03, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that Craig Fraser , President and Chief Executive
Day Zero Diagnostics Names Jeff Mirviss Chair of Board of Directors
Day Zero Diagnostics announced today that independent board member, Jeff Mirviss, has been appointed board chair.
Day Zero Diagnostics Names Jeff Mirviss Chair of Board of Directors
Day Zero Diagnostics announced today that independent board member, Jeff Mirviss, has been appointed board chair.